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Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. In Singapore, HCC has an ageastandardized 
incidence rate of about 19 per 100 000 per year,1 and 
is commonly associated with chronic hepatitis B virus 
(HBV) infection in the local population. Surgical reseca
tion is the only treatment that offers possible cure, but 
the majority of patients present with advanced, unrea
sectable disease, and only 9% to 27% are suitable for rea
section.2,3 Reasons for inoperability are commonly the 
presence of advanced cirrhosis, a large primary lesion, 
multifocal disease, invasion or thrombosis of major 
blood vessels, and poor liver function. These patients 
have a median survival of 4.1 months.4 
Single agent systemic chemotherapy has been used 
to treat inoperable HCC with only modest efficacy. 
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BACKGROUND: chemotherapeutic treatment options for advanced unresectable and/or metastatic hepatocel-
lular carcinoma (hcc) are limited. currently available treatments are associated with low response rates and 
little evidence of improved survival, so we evaluated a new chemoimmunotherapy regimen.
METHODS: seven patients with unresectable and/or metastatic hcc were treated with intravenous oxaliplatin 
(30mg/m2) and doxorubicin (20mg/m2) given on days 1, 8 and 15 in a 28-day cycle, a daily continuous infu-
sion of fluorouracil (200mg/m2) and subcutaneous interferon alfa-2b 5 mu administered thrice weekly (oXafi). 
treatment was administered to a maximum of six cycles. data on the response to treatment, toxicity, surgical 
procedures and survival outcome was reviewed.
RESULTS: the best response was three partial responses, three stable disease responses and one progressive 
disease response. two patients underwent interval hepatic resection, and histological analysis in one patient 
showed a complete pathological response. another patient underwent a liver transplant after four cycles of 
treatment. these three patients were alive with no evidence of disease at 23, 21 and 18 months follow-up, re-
spectively. at a median follow-up of 14 months (range 2-23 months), one patient died 2 months after diagnosis 
due to progressive disease, while all six other patients were alive. neutropenia was the predominant toxicity, but 
there were no episodes of febrile neutropenia, hospital admissions or deaths. there were no cases of hepatitis 
b virus re-activation. 
CONCLUSIONS: oXafi shows activity in hcc and has manageable toxicity. complete pathological remission 
is possible with this regimen.
Various clinical trials have demonstrated response rates 
of 0% to 20% with singleaagent chemotherapy in HCC. 
Among these agents, anthracyclines such as doxorubia
cin have been the most effective, yielding response rates 
of up to 20% and a median survival of 4 months.5a8 
Other agents that have shown some activity are fluoroa
uracil,9,10 cisplatin,11 gemcitabine,12 and oxaliplatin.13a15 
Interferons have been reported to have a modest degree 
of activity in HCC.16 Interferons have immunomodulaa
tory and antiproliferative effects on tumor cells,17 and 
in one randomized study, interferons were reported to 
be superior to doxorubicin in terms of survival, tumor 
response, and toxicity in patients with HCC.18 Various 
combinations of chemotherapy including doxorubicin, 
cisplatin, and fluorouracil, with or without interferon, 
have been studied.19,20 Synergism between continuous 
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infusion fluorouracil and interferon has been noted 
and previous studies of continuous infusion fluorouraa
cil and interferon have yielded complete responses to 
treatment.21,22 Individual reports on combination chea
motherapy19,20 have yielded higher response rates than 
those found for single agents historically.8,10 Several rea
ports of gemcitabine combinations have been promisa
ing, in particular. A phase II study of gemcitabine and 
oxaliplatin yielded a response rate of 18% with a disease 
stabilization rate of 58%.14 A phase II study of a regimen 
consisting of doxorubicin, cisplatin, fluorouracil, and ina
terferon (referred to as PIAF) showed a response rate of 
26% in 50 patients with unresectable HCC, and a 28% 
stable disease rate.19 Nine of 13 patients with partial rea
sponses proceeded to have surgical resection, and 4 paa
tients had a pathological complete response on surgical 
resection and median survival of 8.9 months. However, 
a subsequent phase III study of PIAF compared with 
single agent doxorubicin showed a nonasignificant 
higher response rate for PIAF (20.9% vs 10.5%) and no 
significant difference in overall survival.23 PIAF had siga
nificantly more grade 3 and 4 toxicities (neutropenia and 
thrombocytopenia in 82% and 57%, respectively). Forty 
percent of patients had HBV reactivation and of these, 
30% died from liver failure. 
OXAFI consists of intravenous oxaliplatin (30 mg/m2), 
doxorubicin (20mg/m2), daily continuous infusion of 
fluorouracil (200mg/m2) and subcutaneous interferon 
alfaa2b. This regimen has the potential advantages 
of reduced myelotoxicity due to relatively low weekly 
dosing of oxaliplatin and doxorubicin as well as cona
tinuous infusion of fluorouracil. OXAFI is only mildly 
emetogenic due to the weekly dosing regimen, and thus 
the use of steroids as antiaemetics is reduced and the 
frequency of HBV flare may be lowered. Steroids dia
rectly induce nuclear transcription leading to HBV via
ral replication.24 The thrice weekly dosing of interferon 
may also further lower the risk of HBV flare as it is the 
method used to treat chronic hepatitis related to HBV.25 
Finally, the OXAFI regimen may have the advantage of 
the antiaangiogenic properties of metronomic chemoa
therapy by way of low dose thriceaweekly interferon, 
weekly administration of oxaliplatin, doxorubicin, and 
continuous infusion fluorouracil.26 In this case series, 
we report our preliminary experience with OXAFI in 
patients with advanced HCC.
PATIENTS AND METHODS
Between December 2005 and March 2007, a total of 7 
patients with unresectable and/or metastatic HCC were 
treated with OXAFI regimen at our center. The diagnoa
sis of HCC was made either by histological examination 
of tumor tissue or by nonahistological criteria (estaba
lished hepatic cirrhosis due to hepatitis B/C, or ethaa
nol; alphaafetoprotein [AFP] level greater than 500ng/
mL; focal lesion in the liver on imaging). The lesion was 
deemed unresectable either due to the presence of disa
tant metastases, and/or by local tumor characteristics 
(large primary lesion, multifocal disease, vascular invaa
sion ) or poor liver function. Chemoimmunotherapy 
treatment consisted of intravenous oxaliplatin (30mg/
m2) and doxorubicin (20mg/m2) given on days 1, 8 and 
15 in a 28aday cycle, daily continuous infusion of fluoa
rouracil (200mg/m2) and subcutaneous interferon alfaa
2b 5 MU administered thrice weekly (OXAFI) (Table 
1). Before weekly doses of oxaliplatin and doxorubicin 
patients were preamedicated with 5aHT3 antagonists 
and dexamethasone in a nonacarrier of hepatitis B or 
C, as antiaemetics. In a hepatitis B or C carrier, dexaa
methasone administration was omitted. All treatment 
was administered on an outpatient basis. A maximum 
of 6 cycles of treatment was administered. 
Response evaluation
All patients underwent a baseline ultrasound/CT or 
MRI scan together with renal and hepatic function tests 
and a full blood count prior to commencing treatment. 
Patients were seen once every 28 days and tumor evaluaa
tion via CT or MRI imaging was performed every 2 cya
cles. AFP levels were repeated every cycle. Classification 
of response on imaging was in accordance with RECIST 
(Response Evaluation Criteria in Solid Tumors)27 critea
ria. Complete response (CR) was defined as complete 
disappearance of all target lesions on radiological moa
dalities and normalization of the AFP level for at least 
4 weeks. Partial response (PR) was defined by at least a 
30% decrease in the sum of the longest diameter (LD). 
Stable disease (SD) was defined by a <30% decrease, or 
not more than a 20% increase in the LD. The best rea
sponse to OXAFI treatment was recorded.
Treatment was discontinued if there was disease 
progression, intercurrent illness preventing further ada
ministration of treatment, adverse events, hepatitis flare, 
any cardiac event, insufficient patient compliance, or by 
patient choice. If there was a response to chemotherapy, 
the patient was referred to the surgical team for considera
ation of interval curative hepatic resection. In the event of 
surgery, OXAFI was stopped at least 2 weeks prior and 
restarted 4 weeks after surgery at the earliest. The maxia
mum number of chemotherapy cycles administered was 
six. If surgery could not be performed, a maximum total 
of 6 cycles of OXAFI were completed. Overall survival 
was measured from the time of initiation of OXAFI to 
time of death or last contact.
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Table 1. OXAFI single-cycle schedule.
Dose Week 1 Week 2 Week 3 Week 4
IV oxaliplatin 30 mg/m2 (D1) (D8) (D15) -




200 mg/m2/day Continuous infusion daily for 28 days













D: Day; M/T/W/TH/F/S: Monday/Tuesday/Wednesday/Thursday/Friday/Saturday
Table 2. Clinical characteristics of the seven patients treated with OXAFI.
Patient 1 2 3 4 5 6 7
Age 57 54 54 34 62 50 50
Gender Female Male Male Male Male Male Male
AJCC stage III T3N0M0 III T3N0M0 II T2N0M0 IV T3N0M0 III T3N0M0 III T3N0M0 III T3N0M0
Largest diameter of 
primary lesion (cm) 5.0 16.4 4.6 13.0 9.6 13.3 15.0
Vascular 
involvement + – – – – + –
Child-Pugh score A A B A A B A
Hepatitis B status + + – + – + +
ECOG 0 0 0 1 1 1 0
No. of cycles 
received 6 4 3 5 2 1 3
Best response 
base on CT RECIST 
criteria
PR SD SD PR SD PD PR
AFP at diagnosis 
(µg/L) 6244 3.6 13 7617 5.5 96 190 48 556
AFP after 2 
cycles (µg/L) 148 4.4 7.1 3682 6.9 - 3953
AFP after 4 















Status Alive Alive Alive Alive Alive Dead Alive
Survival (months) 23 18 21 13 14 2 8
AJCC: American Joint Commission on Cancer; ECOG: Eastern Cooperative Oncology Group Performance Score; AFP: Alpha-fetoprotein; RECIST: Response Evaluation Criteria in Solid 
Tumors; PR: partial response; SD: stable disease; PD: progressive disease
RESULTS
The median age of the patients was 54 years (Table 
2). Five patients had American Joint Commission on 
Cancer28 (AJCC) stage IIIA (T3N0M0) disease, 1 
had stage II (T2N0M0) disease and 1 had stage IV 
(T3N0M1) disease with lung metastases at presentaa
tion. Five patients with stage II and III disease were 
unresectable due to large primary lesions and/or the 
presence of portal vein thrombosis, and one patient was 
unresectable due to the presence of Child’s B liver cira
rhosis. Five patients were positive for hepatitis B infeca
tion and of these, one (patient 4) was taking lamivudine 
original research report OXAFI FOR HEPATOCELLULAR CARCINOMA
Hematol Oncol Stem Cell Ther 1(3)     July 2008 hemoncstem.edmgr.com162
therapy. One patient had a history of alcoholic liver cira
rhosis. Five patients had a ChildaPugh score of A and 2 
were ChildaPugh score B. All patients had an Eastern 
Coaoperative Oncology Group (ECOG) performance 
status of 0a2. Four patients had elevated AFP at the 
time of initial diagnosis. All patients were chemonaive 
except for patient 4, who had previously been treated 
with transarterial chemoembolization. 
OXAFI chemoimmunotherapy
Patients 1, 2, 3, 5, 6 and 7 were started on OXAFI 
at the doses and as per the schedule described for a 
maximum of 6 cycles. In patient 4, oral capecitabine 
(500mg/m2) twice daily was substituted for intravea
nous fluorouracil infusion due to logistical reasons. 
Patient 3 was also switched from intravenous fluoa
rouracil to oral capecitabine (500mg/m2) from cycle 
2 onwards due to patient request. The total number 
of cycles of OXAFI administered was 24, and the ava
erage number of chemotherapy cycles given was 3.4; 
only patient 1 completed all six cycles of treatment. 
Reasons for discontinuation of therapy were stable 
disease (patient 2, 3, 5, 7) and progressive disease (paa
tient 4, 6).
The best response recorded based on CT RECIST 
criteria was three partial, three stable disease and one 
progressive disease responses (Table 2), giving an inia
tial response rate of approximately 43%. Patients 1, 4 
and 7 had a partial response on the CT scan and AFP 
levels after two cycles of chemotherapy (Figure 1) and 
patients 2, 3 and 5 had stable disease. Patient 1 undera
went hepatic resection after two cycles of OXAFI and 
histological analysis of the resection specimen showed 
pathological complete response (Figure 2). Patient 4 
completed five cycles of chemotherapy, with an inia
tial partial response after two cycles of treatment; 
however, a later CT scan showed progressive disease 
and chemotherapy was discontinued. Patient 7 also 
showed an initial partial response after two cycles, but 
subsequent stabilization of disease after three cycles 
of chemotherapy.
Surgical procedures
Three patients underwent hepatic resection. Patient 1 
had a partial response after 2 cycles of treatment with 
resolution of portal vein thrombosis on CT, and proa
ceeded to have interval hepatic resection after three cycles 
of OXAFI. Histological analysis showed a pathological 
complete response and the patient proceeded to complete 
three further cycles of chemotherapy. Patient 2 had stable 
disease after 4 cycles of treatment and proceeded to have 
a cadaveric liver transplant. Patient 3 had stable disease 
after three cycles of OXAFI and underwent interval liver 
resection with clear margins obtained. 
Survival and disease outcome
At a median followaup of 14 months (range, 2a23 
months), 1 patient (patient 6) had died 2 months after 
diagnosis due to progressive disease, while all six other 
patients were still alive. Patients 1, 2 and 3 underwent 
hepatic resection and were alive with no evidence of disa
ease recurrence at followaups of 23, 18 and 21 months, 
respectively. Patients 4, 5, and 7 were receiving other 
treatments at the time of writing. 
Toxicity of chemotherapy
The only grade 3/4 toxicity seen was neutropenia, 
which was experienced by four patients, but there were 
no episodes of febrile neutropenia. The most coma
mon nonahematological toxicity encountered during 
treatment was grade 2 mucositis in three patients and 
grade 1a2 fatigue in four patients (Table 3). There were 
no treatmentarelated deaths or hospital admissions. 
Treatment delays and dosage reductions were required 
in five patients due to neutropenia. There were no cases 
of hepatitis B reaactivation in our population. 
Figure 1A. CT scan showing pre-treatment liver lesion of 5.0×4.5 cm.
Figure 1B. CT scan showing interval reduction in size to 2.9×3.6 cm 
after two cycles of OXAFI.
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Table 3.  Treatment-related toxicity.
Toxicity (NCI-CTC)
No. of patients
Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 1 1 3 1
Thrombocytopenia 0 1 0 0
Anemia 0 2 0 0
Alopecia 3 4 - -
Diarrhea 2 0 0 0
Nausea/vomiting 2 0 0 0
Stomatitis 0 3 0 0
Hand-foot 
syndrome 2 0 0 0
Neurotoxicity 0 1 0 0
Fatigue 3 1 0 0
NCI-CTC: National Cancer Institute - Common Toxicity Criteria
DISCUSSION
Treatment options in advanced HCC are limited. 
Although surgery offers the only hope of cure for HCC, 
only a small proportion of patients are resectable at the 
time of diagnosis. For the remaining patients with inopa
erable and metastatic disease, the prognosis is dismal. 
For disease that is confined to the liver, local treatment 
options such as intraaarterial infusion of combination 
chemotherapy, chemoembolization, radiofrequency aba
lation, and percutaneous ethanol injection offer some 
palliation, but these modalities are unsuitable for paa
tients with extraahepatic disease, a large primary lesion 
or multiafocal disease, a blocked portal venous system 
or established liver cirrhosis. Patients who are unable 
to undergo local therapies are treated with various coma
binations of chemotherapies, albeit with limited suca
cess and little survival benefit. More recently, targeted 
agents such as sorafenib, a multikinase inhibitor with 
antiaangiogenic, proaapoptotic and Raf kinase inhibia
tory activity have been shown to have a 44% improvea
ment in overall survival benefit compared with placebo 
in advanced HCC and with a median survival of 10.7 
months (treatment group) versus 7.9 months in the plaa
cebo group.29
Response to chemotherapy and survival in HCC, in 
addition to tumor characteristics, is influenced by una
derlying hepatic function, the presence of hepatitis B 
infection, and by the toxicity of the chemotherapy regia
men. In this study, we studied a new regimen, OXAFI, 
which consisted of weekly oxaliplatin, doxorubicin, cona
tinuous infusion fluorouracil and thrice weekly intera
feron in patients with advanced HCC. OXAFI had the 
potential advantages of reduced myelotoxicity, reduced 
emetogenicity and hence reduced use of steroids, and a 
reduction in the risk of HBV flare due to the reduced 
use of steroids as well as concurrent use of interferon, 
and it may have antiaangiogenic properties. 
Two patients in this case series received oral 
capecitabine instead of infusional fluorouracil due to 
logistical reasons. Capecitabine has shown equivaa
lence with fluorouracil/leucovorin in adjuvant as well 
as metastatic colon cancer,30a32 and is effective as an 
alternative to infusional fluorouracil in the treatment 
of advanced esophagogastric cancer.33 The combinaa
tion of capecitabine and oxaliplatin was shown to be 
nonainferior to FOLFOX in metastatic colon cancer.34 
Capecitabine has also demonstrated efficacy in combia
nation with oxaliplatin for treatment of advanced HCC 
in the FFCD 03a03 trial with a disease control rate of 
72%.35
OXAFI resulted in three initial partial responses, 
three stable disease reponsees and one progressive 
Figure 2. Sections of the resection specimen (from patient 1) demonstrating changes 
compatible with post-chemotherapy effect on hepatocellular carcinoma. No residual 
tumor is seen (hematoxylin-eosin, A: ×20, B: ×40; C: ×100; D: ×200).
A B
C D
disease response with survival ranging from 2 to 23 
months. Eight of nine patients were alive at a median 
followaup of 14 months. Two patients with initially una
resectable disease underwent successful surgical reseca
tion, one of which had a complete pathological response 
on histological examination. 
The toxicity of OXAFI was manageable and was 
mainly limited to neutropenia in no more than half 
of the patients, but there were no episodes of febrile 
neutropenia and no treatmentarelated deaths. No paa
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